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Biologically active proteins without stable tertiary structure are common in all known
proteomes. Functions of these intrinsically disordered proteins (IDPs) are typically related
to regulation, signaling, and control. Cellular levels of these important regulators are tightly
regulated by a variety mechanisms ranging from firmly controlled expression to precisely
targeted degradation. Functions of IDPs are controlled by binding to specific partners,
alternative splicing, and posttranslational modifications among other means. In the norm,
right amounts of precisely activated IDPs have to be present in right time at right places.
Wrecked regulation brings havoc to the ordered world of disordered proteins, leading
to protein misfolding, misidentification, and missignaling that give rise to numerous
human diseases, such as cancer, cardiovascular disease, neurodegenerative diseases, and
diabetes. Among factors inducing pathogenic transformations of IDPs are various cellular
mechanisms, such as chromosomal translocations, damaged splicing, altered expression,
frustrated posttranslational modifications, aberrant proteolytic degradation, and defective
trafficking. This review presents some of the aspects of deregulated regulation of IDPs
leading to human diseases.
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INTRODUCTION
For more than a 100 years, it was believed that unique protein
function is defined by the unique 3-D structure of a protein,
which, in its turn, is defined by a unique amino acid sequence
(Fischer, 1894), and the validity of this “one sequence—one
structure—one function” concept was unquestioned for a long
time, especially after the crystal structures of proteins started to be
solved by X-ray diffraction. However, research, especially during
the past 15 years, clearly indicated that the lack of stable tertiary
and/or secondary structure does not preclude proteins from being
biologically active (Wright and Dyson, 1999; Uversky et al., 2000;
Dunker et al., 2001; Tompa, 2002; Uversky and Dunker, 2010). In
fact, many proteins with crucial biological functions exist as col-
lapsed or extended dynamically mobile conformational ensem-
bles and do not have unique well-defined 3D structures as a whole
or in their noticeable parts (at least in in vitro experiments). These
proteins are known as intrinsically disordered proteins (IDPs) or
hybrid proteins possessing both structured domains d biologi-
cally important intrinsically disordered protein regions (IDPRs).
In addition to foldable (ordered) and non-foldable (intrinsically
disordered) proteins, many proteins are known to misfold. Often
such misfolding is accompanied by protein aggregation caus-
ing several human diseases that originate from the deposition
of protein aggregates formed from specific proteins or protein
fragments, which accumulate in a variety of organs and tissues
(Kelly, 1998; Bellotti et al., 1999; Dobson, 1999; Uversky et al.,
1999a,b; Rochet and Lansbury, 2000; Uversky and Fink, 2004;
Gasperini et al., 2012;Moreau and King, 2012; Safar, 2012;Walker
and LeVine, 2012; Cuanalo-Contreras et al., 2013; Mulligan and
Chakrabartty, 2013; Hipp et al., 2014). More than 20 different
proteins are known so far to be involved in these diseases referred
to as amyloidoses. Furthermore, many other diseases [such as
cancer or cardiovascular disease (CVD)] are caused by the mis-
folded and therefore dysfunctional proteins (Iakoucheva et al.,
2002; Cheng et al., 2006; Uversky, 2008a, 2009, 2014; Uversky
et al., 2008, 2009; Uversky and Dunker, 2010). Therefore, natural
proteins can be found in one of three major protein forms, func-
tional and folded, non-functional and misfolded, and functional
and intrinsically disordered.
The structural plasticity and conformational adaptability of
IDPs/IDPRs, their ability to react easily and quickly in response to
changes in their environment, and their binding promiscuity and
unique capability to fold differently while interacting with differ-
ent binding partners (Dyson and Wright, 2005; Oldfield et al.,
2008) define a wide set of functional advantages of IDPs/IDPRs
over the ordered proteins (Uversky and Dunker, 2010; Cozzetto
and Jones, 2013; Ferreon et al., 2013). These factors determine the
abundant involvement of IDPs/IDPRs in various signaling, regu-
lation, and recognition processes. They also allow these flexible
proteins to play diverse roles in modulation and control of func-
tions of their binding partners and in promotion of the assembly
of supra-molecular complexes. In fact, IDPs are promiscuous
binders and can form highly stable complexes, or be involved
in signaling interactions where they undergo constant “bound-
unbound” transitions, thus acting as dynamic and sensitive “on-
off” switches. The ability of these proteins to return to the
highly flexible conformations after the completion of a particular
function, and their predisposition to adopt different conforma-
tions depending on their environment, are unique physiological
properties of IDPs which define the ability of these proteins to
exert different functions in different cellular contexts according
to a specific conformational state (Uversky and Dunker, 2010).
Furthermore, biological activities of IDPs/IDPRs are known
to be precisely and tightly controlled and regulated by extensive
posttranslational modifications (PTMs), such as phosphoryla-
tion, acetylation, glycosylation, etc. (Collins et al., 2008; Uversky
and Dunker, 2010; Kurotani et al., 2014; Pejaver et al., 2014),
and by alternative splicing (AS) (Romero et al., 2006; Buljan
et al., 2012, 2013). The ability of AS to generate extended
sets of protein isoforms with highly diverse regulatory elements
(Romero et al., 2006) is determined by the mosaic structure
of IDPs/IDPRs that are known to contain multiple relatively
short, functional elements, which, being spread within the amino
acid sequences, define the multifunctionality of these proteins
(Uversky, 2013). Clearly, AS-driven removal of pieces of the
IDP/IDPRs sequence containing different functional elements
could dramatically reshuffle such multifunctionality (Buljan
et al., 2012, 2013; Colak et al., 2013).
Careful examination of different proteomes and various large
protein datasets (e.g., UniProt database, http://web.expasy.org/
docs/swiss-prot_guideline.html) by various disorder predictors
revealed that IDPs are not some obscure and rare exceptions
from the general “one sequence—one unique structure—one
unique function” paradigm (Wright and Dyson, 1999; Uversky
et al., 2000; Dunker et al., 2001; Tompa, 2002), but, in fact, are
highly abundant in nature (Dunker et al., 2000; Ward et al., 2004;
Tompa et al., 2006; Krasowski et al., 2008; Shimizu and Toh,
2009; Tokuriki et al., 2009; Pentony and Jones, 2010; Tompa and
Kalmar, 2010; Uversky, 2010a; Xue et al., 2010a, 2012a; Dyson,
2011; Schad et al., 2011; Hegyi and Tompa, 2012; Korneta and
Bujnicki, 2012; Midic and Obradovic, 2012; Pancsa and Tompa,
2012; Di Domenico et al., 2013; Kahali and Ghosh, 2013). These
natural abundance of IDPs and IDPRs are now documented in
multiple entries populating various disorder-related databases,
such as DisProt (Vucetic et al., 2005; Sickmeier et al., 2007), D2P2
(Oates et al., 2013), Ideal (Fukuchi et al., 2012, 2014), MobiDB
(Di Domenico et al., 2012), ComSin (Lobanov et al., 2010), and
pE-DB (Varadi et al., 2014). The overall amount of IDPs and
IDPRs in various proteomes increases with the increase in the
organism’s complexity, with over half of all eukaryotic proteins
predicted to contain long IDPRs (Dunker et al., 2000; Ward et al.,
2004; Oldfield et al., 2005; Uversky, 2010a; Xue et al., 2012a). It is
believed that the potential explanation for this trend has its roots
in a change in the cellular requirements for certain protein func-
tions, particularly for proteins involved in cellular signaling. In
agreement with this hypothesis, a computational analysis revealed
that the majority of known eukaryotic signaling proteins contain
significant regions of disorder (Dunker et al., 2002; Iakoucheva
et al., 2002).
Many individual IDPs and hybrid proteins (e.g., α-synuclein,
p53, PTEN, etc.) are known to interact with large number of
unrelated partners, thereby serving as hubs in cellular protein-
protein interaction networks (Dunker et al., 2005; Uversky et al.,
2005). Also, the binding regions of partner proteins interacting
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with structured hubs, such as 14-3-3 and calmodulin, are often
intrinsically disordered (Bustos and Iglesias, 2006; Radivojac
et al., 2006). Therefore, there are two general mechanisms by
which intrinsic disorder is exploited in protein-protein interac-
tion networks, where one IDP/IDPR binds to many partners and
many IDPs/IDPRs interact with one partner (Dunker et al., 2005;
Uversky et al., 2005). Subsequent comprehensive bioinformatics
studies supported the hypothesis that hub proteins commonly use
disordered regions to bind to multiple partners (Dosztanyi et al.,
2006; Ekman et al., 2006; Haynes et al., 2006; Patil and Nakamura,
2006; Singh and Dash, 2007; Singh et al., 2007).
IDPs IN HUMAN DISEASES
A GENERAL OVERVIEW OF THE IDP INVOLVEMENT IN PATHOGENESIS
OF VARIOUS MALADIES
Since IDPs/IDPRs are very common in all proteomes studied
to date, possess numerous crucial functions, are promiscuous
binders, are abundantly involved in signaling, control, and reg-
ulation of important biological processes, where it is crucial
for a given protein to be available in appropriate amounts and
not to be present longer than needed, IDPs and hybrid pro-
teins have to be tightly regulated and controlled themselves. To
check this hypothesis, careful analysis of the IDP regulation inside
the cell at different stages of protein synthesis and degradation
was recently conducted using the corresponding data available
for the Saccharomyces cerevisiae, Schizosaccharomyces pombe, and
Homo sapiens proteomes (Gsponer et al., 2008). This analysis
revealed that IDPs were less abundant than ordered proteins
in these tree proteomes because of the increased decay rates of
mRNAs encoding IDPs, lower rates of IDP protein synthesis, and
shorter half-lives of IDPs (Gsponer et al., 2008). Also, the major-
ity of IDP-targeting kinases were either regulated in a cell-cycle
dependent manner, or were activated upon exposure to specific
stimuli or stress (Gsponer et al., 2008), thereby adding another
level of the IDP control. It is important to remember though
that although the abundance of many IDPs is tightly regulated,
some disordered, and hybrid proteins are present in cells in large
amounts [for example, α-synuclein constitutes ∼1% of the total
soluble protein in the brain (Iwai et al., 1995)] or/and for long
periods of time due to either specific PTMs, or via interactions
with other factors, or due to the localization is specific compart-
ments (Uversky and Dunker, 2010). These events could promote
changes in cellular localization of IDPs or protect them from
degradation (Dunker et al., 2001; Iakoucheva et al., 2004; Tompa,
2005; Grimmler et al., 2007). Therefore, accumulated data clearly
show that the chaos seemingly associated with highly flexible and
promiscuous IDPs/IDPRs is under tight control (Uversky and
Dunker, 2008).
In addition to mentioned bioinformatics analyses numerous
experimental studies not only emphasize the important roles of
disordered regulators in signaling (Mitrea and Kriwacki, 2013;
Follis et al., 2014), regulation (Galea et al., 2008a; Wang et al.,
2011; Follis et al., 2012; Mitrea et al., 2012; Ou et al., 2012; Yoon
et al., 2012; Frye et al., 2013; Moldoveanu et al., 2013), cell protec-
tion (Mei et al., 2014), protein protection (De Jonge et al., 2009;
Chakrabortee et al., 2012), and cellular homeostasis (Norholm
et al., 2011; Follis et al., 2013), but also show that IDPs/IDPRs are
concisely controlled by themselves via multiple mechanisms, such
as interaction with chaperones (Rudiger et al., 2002; Martinez-
Yamout et al., 2006; Rodriguez et al., 2008; Didenko et al., 2012;
Karagoz et al., 2014) or nanny proteins (Tsvetkov et al., 2009a),
partner binding (Demarest et al., 2002; Chipuk et al., 2008; Ebert
et al., 2008; Ferreon et al., 2009a,b; Wojciak et al., 2009; Lee et al.,
2010), various PTMs (Kostic et al., 2006; Grimmler et al., 2007;
Zhan et al., 2007; Galea et al., 2008b; Mitrea et al., 2014), and
regulated degradation (Asher et al., 2005; Tsvetkov et al., 2008,
2009b, 2012; Suskiewicz et al., 2011; Wiggins et al., 2011).
Obviously, when tightly controlled process is suddenly coming
out of control, consequences could be disastrous. In agreement
with this statement, numerous cases are known where the mal-
function of a protein (which could be ordered or intrinsically
disordered) is associated with the development of particular
pathological conditions, and a broad range of human diseases
is linked to the failure of a specific peptide or protein to adopt
its functional conformational state. Each of these conformational
diseases originates from the dysfunction of a particular protein.
The failure of such a protein to adopt, possess, or keep functional
state is commonly associated with protein misfolding, loss of
normal function, gain of toxic function, and/or protein aggrega-
tion (Uversky et al., 2009; Uversky, 2010b). Some disease-related
proteins have an intrinsic propensity to form pathologic con-
formation(s). For other proteins, interactions or impaired inter-
actions with chaperones, intracellular or extracellular matrices,
other proteins, small molecules, and other endogenous factors
can induce conformational changes and increase propensity to
misfold. Often, misfolding, and dysfunction originate from point
mutation(s) or result from a protein exposure to internal or exter-
nal toxins. Furthermore, such conformational diseases can also
be caused by impaired PTMs, such as phosphorylation, advanced
glycation, deamidation, racemization, etc., an increased probabil-
ity of degradation, impaired trafficking, loss of binding partners,
or oxidative damage. All these factors can act independently,
additively, or synergistically (Uversky, 2012).
It is recognized now that IDPs and hybrid proteins with long
IDPRs are commonly involved in human diseases. For example,
some well-known cancer-related proteins with experimentally
confirmed IDPRs include p53 (Wells et al., 2008), BRCA1 (Mark
et al., 2005), EWS (Ng et al., 2007), HPV protein (Uversky et al.,
2006), PTEN (Malaney et al., 2013a), axin (AXis Inhibition)
(Noutsou et al., 2011; Xue et al., 2012b, 2013), adenomatous
polyposis coli (APC) protein (Xue et al., 2012b; Minde et al.,
2013), apoptosis-stimulating proteins of p53 (ASPPs) (Rotem
et al., 2007; Ahn et al., 2009), BH3-only proteins (Kvansakul
and Hinds, 2014), sirtuins (McBurney et al., 2013; Sharma et al.,
2013), CBP/?p300 [CREB-binding protein (CBP) and its par-
alog, E1A-binding protein p300] (Wojciak et al., 2009), cell
cycle regulatory proteins p21 and p27 (Mitrea et al., 2012),
and many others. Recent computational analysis revealed that
a majority of the cancer/testis antigens (CTAs) are typical IDPs
(Rajagopalan et al., 2011). CTAs constitute a heterogeneous pro-
tein group, members of which are typically expressed in the
normal testis and aberrantly expressed in several types of cancer
(Rajagopalan et al., 2011). Among the neurodegeneration-related
proteins is such well-characterized IDPs as a protein-chameleon
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α-synuclein that can adopt a variety of different conformations,
starting from random coil and ending with a more compact
molten globular state, or even with poly-(L-proline) II-like con-
formations, depending on the cellular environment (Uversky,
2003), and aggregates of the α-synuclein are accumulated in
Parkinson’s disease, dementia with Lewy bodies, Alzheimer’s
disease (AD), Down’s syndrome, and several other synucle-
inopathies (Uversky, 2007, 2008b; Uversky and Eliezer, 2009;
Breydo et al., 2012; Alderson and Markley, 2013). Other IDPs
implicated in neurodegenerative diseases include amyloid β and
tau proteins (AD), prions (Creutzfeldt-Jakob disease, scrapie,
bovine spongiform encephalopathy), and ataxin (spinocerebellar
ataxia) (Uversky, 2009, 2014). Other human diseases with well-
established pathogenic IDPs are CVDs (hirudin and thrombin)
(Cheng et al., 2006), type II diabetes (amylin) (Uversky et al.,
2008), AIDS (HIV Rev protein) (Casu et al., 2013), and cystic
fibrosis (CFTR) (Baker et al., 2007).
COMPUTATIONAL APPROACHES FOR ESTIMATING THE IDP
ABUNDANCE IN DIFFERENT DISEASES
The fact that IDPs and hybrid proteins with long IDPRs are
commonly associated with the pathogenesis of various human
disorders gave rise to the “disorder in disorders” or D2 con-
cept (Uversky et al., 2008). Here, the dysfunction, misidentifi-
cation, misregulation, misfolding, and missignaling of causative
IDPs/IDPRs are all can be considered as causative factors of
the conformational diseases (Uversky et al., 2008, 2009, 2014;
Uversky, 2009, 2010b, 2012; Midic et al., 2009a,b). Although the
fact of the involvement of individual IDPs and hybrid proteins
with long IDPRs in the pathogenesis of some human maladies is
well-established, the application of specially designed computa-
tional and bioinformatics protocols opens a unique opportunity
for the accurate evaluation of the abundance of IDPs in various
pathological conditions.
The first of these computational approaches is based on the
assembly of specific datasets of proteins associated with a given
disease and the computational analysis of these datasets using a
number of disorder predictors (Iakoucheva et al., 2002; Cheng
et al., 2006; Uversky et al., 2006; Mohan et al., 2008; Uversky,
2008a, 2009). This approach represents an extension of the anal-
ysis of individual proteins to a set of independent proteins.
Such analysis revealed that 79% of cancer-associated and 66%
of cell-signaling proteins contain predicted regions of disorder
of 30 residues or longer (Iakoucheva et al., 2002). Similar anal-
yses revealed that the percentage of proteins with 30 or more
consecutive disordered residues was 61% for proteins associated
with CVD (Cheng et al., 2006). Many CVD-related proteins were
predicted to be entirely disordered, with 101 proteins from the
CVD dataset predicted to have a total of almost 200 specific
disorder-based binding motifs (thus about 2 binding sites per
protein) (Cheng et al., 2006). Finally, the dataset analysis revealed
that intrinsic disorder is commonly found in neurodegenerative
diseases and diabetes (Uversky et al., 2008, 2009).
In a second approach, the abundance of intrinsic disorder was
analyzed in the human diseasome (Midic et al., 2009a), which is a
complex network that systematically links the human disease phe-
nome with the human disease genome (Goh et al., 2007). These
analyses showed that many human genetic diseases are caused by
alterations of IDPs, that different disease classes vary in the dis-
order contents of their associated proteins, and that many IDPs
involved in some diseases are enriched in disorder-based protein
interaction sites (Midic et al., 2009a,b).
Finally, a third approach is based on the evaluation of the
association between the level of intrinsic disorder and a partic-
ular protein function (including the disease-specific functional
keywords) in a set of proteins known to carry out this func-
tion (Vucetic et al., 2007; Xie et al., 2007a,b). In this approach,
it is hypothesized that if intrinsic disorder is important for a
function described by a given keyword, then, a greater level of
predicted disorder would be found in a protein associated with
this keyword than the level of disorder predicted in a protein ran-
domly chosen from the Swiss-Prot (Vucetic et al., 2007; Xie et al.,
2007a,b). To test this hypothesis, functional keywords associated
with at least 20 Swiss-Prot proteins were found and correspond-
ing keyword-associated datasets of proteins were assembled. For
each keyword-associated set, 1000 length-matching and number-
matching sets of random proteins were drawn from Swiss Prot.
Order-disorder predictions were carried out for the keyword-
associated sets and for the matching random sets. If a function
described by a given keyword were carried out by a long region
of disordered protein, one would expect the keyword-associated
set to have a greater amount of predicted disorder compared to
the matching random sets. The keyword-associated set would
be expected to have less prediction of disorder compared to the
random sets if the keyword-associated function were carried out
by structured protein. Given the predictions for the function-
associated andmatching random sets, it is possible to calculate the
p-values, where a p-value > 0.95 suggests a disorder-associated
function, a p-value < 0.05 suggests an order-associated func-
tion, and intermediate p-values are ambiguous (Vucetic et al.,
2007; Xie et al., 2007a,b). This analysis revealed that out of 710
Swiss-Prot keywords, 310 functional keywords were associated
with ordered proteins, 238 functional keywords were attributed
to disordered proteins, and the remainder 162 keywords yield
ambiguity in the likely function-structure associations (Vucetic
et al., 2007; Xie et al., 2007a,b). Furthermore, many diseases were
found to be strongly correlated with proteins predicted to be dis-
ordered (Vucetic et al., 2007; Xie et al., 2007a,b). Contrary to this,
almost no disease-associated proteins were found to be ordered
(Xie et al., 2007a).
WRECKED REGULATION OF IDPs AND DISEASE
The physiological protein function and the ability to be converted
from a normal protein to a pathological form depend on multi-
ple factors which can be grouped into two major classes, genetic
and non-genetic. Genetic factors include pathological mutations,
aberrant splicing, chromosomal translocation, alternative tran-
scription, and altered AS. Non-genetic factors are related to
the peculiarities and levels of protein expression, protein avail-
ability, regulation, interaction patterns, cleavage propensity, and
PTMs. Some illustrative examples of these transforming fac-
tors leading to the appearance of pathological proteins are given
below. Since the association between the pathological mutations
and IDPs/IDPRs was a subject of several research papers and
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reviews, this mechanism of affecting the physiological protein
function will not be discussed in this review, and the interested
readers are encouraged to look for the corresponding informa-
tion in the original works (e.g., Joerger and Fersht, 2007, 2008;
Uversky, 2008b; Midic et al., 2009a,b; Vacic and Iakoucheva,
2012; Vacic et al., 2012; Yates and Sternberg, 2013). Figure 1 is
a scheme illustrating different ways by which aberrant regulation
of IDPs/IDPRs at different levels can result in the development of
pathological conditions.
GENETIC FACTORS: CHROMOSOMAL TRANSLOCATIONS
One of the most radical and obvious ways to generate a patho-
logical protein is chromosomal translocation, which generates
chimeric proteins by fusing segments of two otherwise separated
genes (see Figure 2). Several forms of cancer, such as acute myel-
ogenous leukemia (AML), acute lymphoblastic leukemia (ALL),
chronic myelogenous leukemia (CML), chronic myelomonocytic
leukemia (CMML), primary myelofibrosis (PMF), anaplastic
large cell lymphoma, non-Hodgkin’s lymphoma, Ewing’s sar-
coma (EWS), colorectal cancer (CRC), non-small cell lung can-
cer, lung adenocarcinoma, and sporadic and radiation-associated
papillary thyroid carcinomas are caused by chromosomal translo-
cation. Computational analysis of the 406 translocation-related
human proteins revealed that these oncoproteins are significantly
enriched in intrinsic disorder, with the translocation breakpoints
being mostly located outside the functional domains (Hegyi et al.,
2009). Furthermore, the vicinities of the breakpoint were shown
to be even more disordered than the rest of these already highly
disordered fusion proteins. These observations suggest that high
levels of intrinsic disorder represents an important factor that
helps fusion proteins to escape detection by cellular surveillance
mechanisms that eliminate misfolded proteins and to live long
enough to manifest their altered function(s) (Hegyi et al., 2009).
The authors found that these translocation-generated fusions
enable the long-range structural communication of remote
FIGURE 1 | Schematic representation of different ways by which
aberrant regulation at the genetic level or various posttranslational
(non-genetic) mechanisms can cause pathogenic transformation in an
IDP/IDPR.
binding and/or catalytic domains in the chimeric proteins and
thereby define the acquired oncogenic functions. One of the illus-
trative examples of such acquired oncogenicity is the acquired
intramolecular phosphorylation of the BCR-ABL fusion pro-
tein related to CML and ALL. Here, chromosomal transloca-
tion results in fusion of a Tyr-kinase phosphorylation motif in
BCR with the Tyr-kinase domain within ABL, with disorder of
the intervening region enabling intramolecular phosphorylation
(Hegyi et al., 2009). Another recent example in this category
is the BCR-RET chimeric protein originated from the fusion of
the catalytic domain of the tyrosine kinase (TK) receptor RET
(REarranged during Transfection) with BCR (Ballerini et al.,
2012).
The secondmechanism of generation of oncoproteins by chro-
mosomal translocation is related to fusion of the dimerization
domain with the kinase domain, generating a dimeric hybrid pro-
tein. Monomers comprising this protein are engaged in multiple
mutual intermolecular phosphorylation reactions that promote
auto-activation and generate novel binding sites for signaling
proteins. Examples of this mechanism include various chimeric
proteins, such as constitutively activated TEL-JAK2 fusion (ETS
translocation variant 6 – Janus tyrosine kinase 2 fusion) with
kinase activity in human leukemia (Lacronique et al., 1997); TFG-
ALK (TRK-fused gene - anaplastic lymphoma kinase fusion)
related to anaplastic large cell lymphomas (Roccato et al., 2003);
NPM-ALK (nucleolar phosphoprotein nucleophosmin – anaplas-
tic lymphoma kinase fusion), the chimeric protein that is created
by translocation in non-Hodgkin’s lymphoma and that requires
the activation of its ALK kinase function as a result of oligomer-
ization mediated by the NPM segment (Bischof et al., 1997);
EML4-ALK (echinoderm microtubule-associated protein-like
4− anaplastic lymphoma kinase fusion) found in non-small lung
carcinoma (Soda et al., 2007); TPM3-ALK (Lamant et al., 1999),
TFG-ALK (Hernandez et al., 1999), and ATIC-ALK (Trinei et al.,
2000) fusions in anaplastic large cell lymphoma (ALCL) (Marino-
Enriquez and Dal Cin, 2013). Other ALK fusion partners include
tropomyosin 4 (TPM4); clathrin heavy chain (CLTC); moesin
(MSN); the cysteinyl-tRNA synthetase (CARS); RNF213, a ring
finger protein; RAN binding protein 2 (RANBP2); myosin II
heavy chain type A (MYH9); vinculin (VCL); dynactin (DCTN1);
liprin beta 1 (PPFIBP1); KIF5B, a kinasin family member; KLC1,
FIGURE 2 | Schematic representation of the genetic translocation
mechanism, where instead of two normal functional proteins a hybrid
protein is produced with aberrant biological activity.
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kinesin light chain 1; and sequestosome 1 (SQSTM1) (Marino-
Enriquez and Dal Cin, 2013). In the vast majority of the ALK-
based fusions, the chimeric proteins include all 563 cytoplas-
mic amino acids from ALK (residues 1058–1620), which is the
constitutively active C-terminal tyrosine kinase domain (Marino-
Enriquez and Dal Cin, 2013), whereas the ALK fusion partner
determines the subcellular localization of the fusion oncopro-
tein via its peptide localization signals and its homotypic or
heterotypic oligomerization domains, which in turn will condi-
tion the protein-protein interactions and modulate the oncogenic
signaling and molecular consequences of the ALK oncoprotein
action (Marino-Enriquez and Dal Cin, 2013). Another highly
promiscuous chromosomal translocator is RET, the catalytic
domain of which, in addition to the aforementioned BCR-RET
fusion, is fused with the heterologous oligomerization domains
encoded by different genes, such as H4 (for RET-PTC1), RIα
(RET-PTC2), ELE1 (RET-PTC3 and RET-PTC4), RFG5 (RET-
PTC5), hTIF (RET-PTC6), RFG7 (RET-PTC7), kinectin (RET-
PTC8), RFG9 (RET-PTC9), and ELKS (ELKS-RET) (Takahashi,
2001), with KIF5B (KIF5B-RET), or fusion with the fibroblast
growth factor receptor 1 (FGFR1) oncogene partner (FGFR1OP-
RET) (Bossi et al., 2014). In the case of FGFR1OP-RET fusion, the
chimeric protein found in papillary thyroid carcinomas and other
myeloproliferative disorders, such as CML, chronic eosinophilic
leukemia, chronic neutrophilic leukemia, polycytemia vera, PMF,
essential thrombocytosis, myelodysplastic syndromes (MDS),
and CMMLwas shown to display constitutive tyrosine kinase and
transforming activity (Bossi et al., 2014).
Chromosomal translocation can affect transcription factors,
as illustrated by the EWS-ATF or EWS-Fli1 hybrids, where the
DNA-binding elements of transcription factors ATF1 or Fli1 are
fused to the disordered transactivation domain of the EWS onco-
gene to generate an aberrant transcription factor related to Ewing
sarcoma (Ng et al., 2007). Another very interesting example of
the transcription factor whose function is affected by chromo-
somal translocation is the ETV6 protein containing two major
domains, the HLH (helix-loop-helix, residues 40–124) domain
and the ETS domain (residues 340–420) connected by the inter-
nal domain (residues 125–339) (De Braekeleer et al., 2012), whose
gene spans a region of less than 250 kb at band 12p13.1 and con-
sists of 8 exons (Baens et al., 1996). The importance of this protein
is determined by the fact that the ETV6 chromosomal translo-
cations are among the most commonly observed chromosomal
abnormalities in human leukemia and myelodysplastic syndrome
(Baens et al., 1996), where there are 48 chromosomal bands
involved in ETV6 translocations, insertions, or inversions, with
at least 28 translocations being characterized at the molecular
level and 30 ETV6 partner genes being identified (De Braekeleer
et al., 2012). In fact, the ETV6 gene is known to be fused with a
wide array of genes encoding proteins with different functionali-
ties, such as receptor tyrosine kinase genes (e.g., ETV6-PDGFRB,
ETV6-PDGFRA, ETV6-NTRK3, and ETV6-FLT3), non-receptor
tyrosine kinase genes (such as ETV6-ABL1, ETV6-ABL2, ETV6-
JAK2, ETV6-FGFR3, ETV6-SYK, ETV6-FRK, and ETV6-LYN),
transcription factor genes (such as ETV6-RUNX1, MN1-ETV6,
ETV6-ARNT, ETV6-PER1, and ETV6-EVI1), homeobox genes
(such as ETV6-CDX2, PAX5-ETV6, andMNX1-ETV6) and many
other genes (e.g., CHIC2-ETV6, ETV6-MDS2, TTL-ETV6, ETV6-
STL, ETV6-PTPRR, ETV6-NCOA2, ETV6-BAZ2A, ETV6-GOT1,
ETV6-FCHO2, ETV6-IGH, and ETV6-ACSL6) (De Braekeleer
et al., 2012). It is important to emphasize here that the men-
tioned fusions do not include the full-length ETV6 protein.
Furthermore, even fusions of the ETV6 gene with the same target
gene not always will have the same parts of the ETV6 protein. For
example, upon fusion to the PDGFRB gene encoding a cell sur-
face tyrosine kinase receptor for members of the platelet-derived
growth factor family, the resulting ETV6-PDGFRB fusion gene in
myeloproliferative disorders will have exon 4 of the ETV6 gene
fused in-frame to exon 11 of the PDGFRB gene, with the result-
ing chimeric protein containing the HLH domain of ETV6 [ETS
translocation variant 6 (also known as TEL), N-terminal part]
and the tyrosine kinase domain of PDGFRB (platelet-derived
growth factor receptor beta, C-terminal part), whereas in chronic
idiopathic myelofibrosis (CIMF) the fusion of the same two genes
will produce in-frame fusion between full-length ETV6 exon 7, 34
bp derived from ETV6 intron 7 and a truncated PDGFRB exon 12,
giving rise to the chimeric protein retaining the internal domain
of ETV6 which has the ability to bind to corepressors and induce
the transcription-repressive activity of ETV6 (De Braekeleer et al.,
2012).
To bring the aforementioned data on the chromosomal
translocation to the frames of this review, Figure 3 represents
disorder propensities of some of the most promiscuous chromo-
somal translocators, ALK, RET, and ETV6. Figure 3A shows that
the C-terminal domain of ALK, which is included in the vast
majority of ALK-based chimeric proteins, is predicted to have
highly disordered N-terminal and C-terminal tails. Figure 3B
illustrates that the same statement is also applicable to RET, cat-
alytic domain of which (residues 708–114) is fused to many target
proteins and is predicted to be surrounded by long IDPRs. Finally,
Figure 3C shows that the transcription factor ETV6 is predicted
to have two ordered domains (residues 43–145 and 310–420),
which coincide with known functional domains of this protein,
PNT domain (residues 40–124) and DNA-binding ETS domain
(residues 339–420).
GENETIC FACTORS: ABERRANT RNA SPLICING
Intrinsic disorder and alternative splicing
Alternative splicing (AS) of pre-mRNAs, which generates two
or more protein isoforms from a single gene, is believed to be
responsible for tissue specificity of many of the abundant pro-
teins. Estimates indicate that between 35 and 60% of human genes
yield protein isoforms by means of AS mRNA (Stamm et al.,
2005). Regions of mRNA affected by AS were shown to corre-
spond to protein regions enriched in intrinsic disorder (Romero
et al., 2006). The finding that the alternatively spliced regions of
mRNA encode IDPRs with greater frequencies than structured
regions suggests a link between AS and signaling by IDPRs. This
connection constitutes a plausible mechanism that could under-
lie and support cell differentiation, which ultimately gave rise
to the multicellular eukaryotic organisms (Romero et al., 2006).
Furthermore, associating AS with protein disorder enables time-
and tissue-specific modulations of protein functions. Since dis-
order is frequently utilized in protein binding regions, having
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AS of pre-mRNA coupled to regions of protein disorder can
lead to tissue-specific signaling and regulatory diversity (Romero
et al., 2006; Weatheritt and Gibson, 2012). In agreement with
this hypothesis, recent bioinformatics analysis clearly showed that
tissue-specific AS of IDPRs with embedded binding motifs is
responsible for rewiring of protein interaction networks and sig-
naling pathways (Buljan et al., 2012, 2013). Also, in the human
FIGURE 3 | Evaluating the disorder propensities of proteins commonly
affected by chromosomal translocation: ALK (A), RET (B), and ETV6
(C). The disorder propensities are evaluated by the members of the PONDR
family of disorder predictors. Here, scores above 0.5 correspond to
disordered residues/regions. PONDR® VSL2B is one of the most accurate
stand-alone disorder predictors (Obradovic et al., 2005), PONDR® VL3
possesses high accuracy in finding long IDPRs (Obradovic et al., 2003),
PONDR® VLXT is not the most accurate predictor but has high sensitivity
to local sequence peculiarities which are often associated with
disorder-based interaction sites (Dunker et al., 2001), whereas PONDR-FIT
represents a metapredictor which, being moderately more accurate than
each of the component predictors, is one of the most accurate disorder
predictors (Xue et al., 2010b).
proteome, two types of conserved IDPRs, conserved disorder
(i.e., disordered regions where the amino acid sequence is well
conserved) and flexible disorder (i.e., disordered regions where
the amino acid sequence has diverged) were shown to be highly
abundant in proteins with regulatory functions and were highly
enriched in regions of proteins that undergo tissue-specific AS
(Colak et al., 2013).
Altered alternative splicing and diseases
The role of aberrant AS in generating pathogenic proteins is
shown in Figure 4, where the normal splicing results in the
production of normally active protein (left), and where altered
AS generates either inactive protein or a splice variant with
pathological or abnormal activity (right).
Aberrant alternative splicing in cancer. Although the flexibility
of AS constitutes an evolutionary advantage for higher eukary-
otes, it also represents a risk. In fact, strong evidence indicates
that defective AS regulation correlates with the onset and pro-
gression of human cancers (Lee et al., 2006; David and Manley,
2010; Pal et al., 2012; Chen and Miller, 2013; Shkreta et al., 2013;
Biamonti et al., 2014; Chen and Weiss, 2014), and many cancer-
associated genes are regulated through AS suggesting a significant
role of this post-transcriptional regulatory mechanism in the pro-
duction of oncogenes and tumor suppressors (Bonomi et al.,
2013). Therefore, not surprisingly, aberrant AS is considered now
as an important hallmark of cancer (Ladomery, 2013). The phe-
nomenon of cancer-associated (or cancer-promoting) aberrant
splicing is widespread. For example, such aberrant AS events
have been found in tumor suppressor LKB1, reduced levels of
which are found in patients with Peutz-Jeghers Syndrome (PJS),
an autosomal dominant disorder associated with gastrointestinal
polyposis and an increased cancer risk, oncogene KIT associated
with gastrointestinal stromal tumors, cell-cell adhesion protein
CDH17 overexpressed in hepatocellular carcinomas (HCCs) and
in gastric and pancreatic cancer, and a Kruppel-like Zn-finger
FIGURE 4 | Schematic representation of the role of aberrant alternative
splicing in production of pathogenic proteins. Here, normal splicing
results in the production of biologically active protein (left), whereas altered
alternative splicing generates either inactive protein or a splice variant with
an abnormal (pathological) activity (right).
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transcription factor KLF6 that functions as a tumor suppressor
(Srebrow and Kornblihtt, 2006), as well as in genes implicated
in tumor progression (for example, CD44, MDM2, and FHIT)
and in susceptibility to cancer [for example, APC (Adenomatous
polyposis coli protein)] (Kalnina et al., 2005).
Also,∼29% of genome-wide expressed genes were shown to be
differentially and recurrently spliced in AML patients compared
to healthy individuals (Adamia et al., 2014). Among these dif-
ferentially spliced genes were genes encoding several oncogenes,
tumor suppressor proteins, splicing factors and heterogeneous
nuclear ribonucleoproteins, proteins involved in apoptosis, cell
proliferation, and spliceosome assembly (Adamia et al., 2014).
Many of these targets of the aberrant splicing in AML, are proteins
with known enrichment in intrinsic disorder, such as proteins
related to apoptosis (Peng et al., 2013) as well as proteins involved
in spliceosome assembly (Korneta and Bujnicki, 2012; Coelho
Ribeiro Mde et al., 2013). Some of the crucial proteins affected
by AS in prostate cancer [e.g., the androgen receptor (AR), zinc
finger transcription factor Kruppel-like factor 6, Bcl-x, and cyclin
D1] (Sette, 2013) are known to contain IDPRs (McEwan, 2012;
Peng et al., 2013).
Three major players in the prevention of breast cancer are p53,
BRCA1, and PTEN. Mutations in the p53, BRCA1, and PTEN
genes account for about 10% of familial breast and ovarian can-
cer cases overall (Muggia et al., 2011; Okumura et al., 2011).
Furthermore, genes of these proteins undergo extensive AS events
and some splicing variants of these tumor suppressor genes are
associated with cancer (Okumura et al., 2011). These three pro-
teins are known to possess functionally important IDRPs. Since
they are among the well-characterized protein with disorder, they
are considered in more details below.
Although p53 is best known for its role as a tumor suppres-
sor and guardian of the genome (Lane, 1992), besides induction
of cell-cycle arrest, apoptosis, or DNA repair, it is also involved
in many other cellular processes, including senescence and dif-
ferentiation (Vousden and Prives, 2009). p53 gene is expressed
as multiple isoforms (with sometimes antagonistic functions)
due to AS, alternative promoter usage and alternative initiation
of translation (Bourdon, 2007). The human p53 gene tran-
scribes multiple splice variants, which are differentially expressed
in human breast tumors compared with normal breast tissue
(Okumura et al., 2011) and also are differentially expressed
from tumor to tumor (Bourdon et al., 2005). There are four
domains in p53: the unfolded N-terminal translational acti-
vation domain, the structured central DNA binding domain,
and the unstructured C-terminal tetramerization and regula-
tory domain (Oldfield et al., 2008; Uversky and Dunker, 2010).
At the transactivation region, p53 interacts with TFIID, TFIIH,
Mdm2, RPA, CBP/p300, and CSN5/Jab1 among many other pro-
teins (Anderson and Appella, 2004). At the C-terminal domain,
it interacts with GSK3β, PARP-1, TAF1, TRRAP, hGcn5, TAF,
14-3-3, S100B(ββ) and many other proteins (Anderson and
Appella, 2004). p53 serves as a unique example illustrating how
intrinsic disorder brings about binding promiscuity, since the
same short segment near the p53 C-terminus, being disordered
in its unbound form, was shown to bind to four different part-
ners and to adopt different bound conformations. In fact, this
disordered segment adopts an α-helix, a β-strand, and two irregu-
lar structures with very different morphology upon binding to its
four different partners (Oldfield et al., 2008; Uversky and Dunker,
2010).
Another important player in the controlling the breast can-
cer development is BRCA1 (breast cancer type 1 susceptibility
protein), which is the 1863 amino acids protein with an amino
terminal zinc ring finger motif, two nuclear localization signals,
and two C-terminally located BRCT domains. Comprehensive
structural and functional analysis revealed that the long central
region of BRCA1 (residues 170–1645) represents an intrinsically
disordered scaffold for multiple protein-protein and protein-
DNA interactions (Mark et al., 2005). Dysregulation of AS of
BRCA1 has also been indicated to be involved in the formation
of the breast and ovary tumors (Orban and Olah, 2001; Okumura
et al., 2011).
Finally, a few words about PTEN (phosphatase and tensin
homolog, deleted on chromosome TEN), which is a tumor
suppressor on 10q23.3 mutated in many types of cancers
(Blumenthal and Dennis, 2008; Carracedo et al., 2011; Hollander
et al., 2011). In fact, PTEN is the second most frequently mutated
tumor suppressor gene after p53 (Uversky et al., 2014). Also, dif-
ferential expression of PTEN and its splice variants can play a role
in the pathogenesis of sporadic breast cancers (Okumura et al.,
2011). For example, the PTEN splice variants retained intron 3
regions (SV3) and intron 5 regions (SV5) have been found in
breast cancers (Okumura et al., 2011). Structurally, PTEN consists
of the intrinsically disordered N-terminal phosphatidyl inositol
(Dunker et al., 2001; Tompa, 2002)-bisphosphate (PIP2) binding
module (PBM), which allows PTEN to anchor to the mem-
brane (its site of action) via PIP2 molecules; the dual-specificity
lipid and protein phosphatase domain (PD), which contains a
conserved catalytic motif HCKAGKGR; the C2 domain, consist-
ing of positively charged residues that help PTEN to associate
with phosphatidylserine residues in the plasma membrane; and
the C-terminal intrinsically disordered region (C-tail), which
regulates membrane association and stability through several
phosphorylation modifications (Malaney et al., 2013a). A longer
variant of PTEN (PTEN-long) contains additional 173 amino
acids at its N-terminus (the N-173 region). PTEN-long is a prod-
uct of alternative translation initiation at a non-canonical start
site (CTG), which is 519 bps upstream of the canonical ATG
(Hopkins et al., 2013). The N-173 region is similar to the viral
cell-penetrating protein Tat and allows PTEN-long to be secreted
from and taken up by cells at distant locations in the body
(Hopkins et al., 2013). A poly-alanine stretch within the N-173
region is essential to its secretion, while a poly-arginine stretch
is critical for uptake (Hopkins et al., 2013). This N-173 region is
largely disordered (Malaney et al., 2013b).
In CRCs, the AS takes place that affects a c-myc
transcriptional suppressor, the far-upstream element-binding
protein-interacting repressor [FIR, also known as Poly(U)-
binding-splicing factor PUF60], that lack the transcriptional
repression domain within exon 2 (FIRexon2) in CRCs
(Rahmutulla et al., 2013). FIR is predicted to possess two long
IDPRs (residues 1–126 and 300–500), with the N-terminal disor-
dered domain being missing in AS isoforms. The high prevalence
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of AS in transforming growth factor beta receptor 2 (TGFBR2)
has been recently reported in oral squamous cell carcinoma
(OSCC) and in potentially malignant oral disorders (PMDs),
with almost no such event detected in normal tissues (Sivadas
et al., 2014). The AS of TGFBR2 occurred at the non-canonical
splice sites and resulted in a selective exclusion of TGFBR2mRNA
sequences that code for TGFBR2 regions involved in tumor sup-
pressive interactions such as ATM, CLK2, and CDC2, whereas
the TGFBR2 sites related to the tumor promoting interactions
such as interactions with MAPK1, PDK1, and PRKCZ were
maintained in these aberrant transcripts (Sivadas et al., 2014).
As far as potential molecular mechanisms of the aberrant AS
in cancer are concerned, recent study of human primary and
metastatic colon cancer samples clearly indicated that the cancer
proliferation can be driven by the overexpression or amplifi-
cation of a component of the tri-small ribonucleoprotein (tri-
snRNP) spliceosome complex, the pre-mRNA processing factor 6
(PRPF6), which commonly occurs in colon tumorigenesis (Adler
et al., 2014; Lokody, 2014). Another recent study indicated that
the switch of AS that occurs during epithelial-mesenchymal tran-
sition and is correlated with the aggressiveness of breast cancer
correlate and breast cancer metastasis is promoted by the het-
erogeneous nuclear ribonucleoprotein M (hnRNPM), which is
an RNA-binding protein that competes with an epithelial splic-
ing regulator ESRP1 for binding to the same cis-regulatory RNA
elements (Xu et al., 2014). Also, the activity of the spliceo-
some (a large macromolecular complex that mediates splicing
and AS events) and accessory splicing factors is modulated by
their reversible phosphorylation. The kinases and phosphatases
involved in these PTMs significantly contribute to AS regulation,
to its integration in the complex regulative network that con-
trols gene expression in eukaryotic cells and its aberrations that
characterize neoplastic transformation (Naro and Sette, 2013).
Finally, a case of extensive AS of the TMPRSS2-ERG gene
fusion represents an important illustration of the combined
effects of chromosomal translocations and AS (Hu et al., 2008;
Sette, 2013). Here, a member of the ETS transcription factor fam-
ily, ERG that is typically expressed at very low levels in benign
prostate epithelial cells is fused with the androgen-responsive
TMPRSS2 (transmembrane protease serine 2) to generate a
prostate cancer oncogene. The resulting TMPRSS2-ERG hybrid
causes abnormally high expression levels of the transcription fac-
tor in neoplastic cells. Furthermore, this fusion-derived gene was
shown to undergo AS and generated multiple mRNA variants
encoding both full-length ERG proteins and isoforms lacking
the ETS domain. Notably, an increase in the abundance of tran-
scripts encoding full-length ERG was shown to correlate with less
favorable outcomes in prostate cancer patients (Hu et al., 2008).
Aberrant alternative splicing in neurodegeneration. Although
numerous studies confirmed the existence of specific differences
in AS profiles between normal and cancer tissues (Omenn et al.,
2010, 2014; Shkreta et al., 2013), cancers are not the only set of
diseases affected/promoted/caused by altered AS. In fact, brain
has the greatest amount of AS of all human tissues, and therefore
it is quite clear that the aberrant AS of brain proteins is associated
with numerous neurodegenerative diseases. For example, in an
autosomal dominant neurodegenerative disease called frontotem-
poral dementia and parkinsonism linked to chromosome 17
(FTDP-17), patients possess a twofold increase in the 4R:3R ratio
of tau isoforms [i.e., isoforms containing four (4R) or three (3R)
microtubule binding domains, respectively] leading to enhanced
aggregation causing the disease (Philips and Cooper, 2000). In
spinal muscular atrophy (SMA), constitutive AS of the survival
of motor neuron gene (SMN) generates the SMN7 isoform
lacking the region encoded by exon 7. This SMN7 isoform dis-
plays decreased self-oligomerization and is unable to participate
in the assembly of small nuclear ribonucleic particles (snRNPs),
thereby affecting the biogenesis and localization of spliceoso-
mal snRNPs in the cell and dramatically reducing the ability of
cells to produce functional mRNAs (Philips and Cooper, 2000).
In Parkinson’s disease, six genes, including PARK2, SNCAIP,
LRRK2, SNCA, SRRM2, and MAPT, are affected by aberrant
AS (Fu et al., 2013). One of these genes, SNCA, encodes
the most studied neurodegeneration-related IDPs, α-synuclein,
aggregation propensity of which is modulated by AS (Beyer,
2006; Beyer and Ariza, 2013). Furthermore, a link between the
α-synuclein AS and risk of sporadic Parkinson’s disease has
been established (Pihlstrom and Toft, 2011). Regulated AS of
another classical neurodegeneration-related IDP, tau protein,
produces multiple isoforms controlling function of this pro-
tein in normal brain by influencing tau localization, conforma-
tion, post-translational modifications, availability, and affinity for
microtubules and other ligands, whereas aberrations in tau splic-
ing directly cause several neurodegenerative diseases, sporadic,
and familial “tauopathies,” exemplified by AD, frontotemporal
dementia with Parkinsonism (FTDP-17), Down syndrome (DS;
trisomy 21), and myotonic dystrophy type 1 (DM1) (Andreadis,
2012). In general, the global transcriptome analysis by exon
arrays and next-generation sequencing (NGS) techniques (e.g.,
RNA-Seq) revealed that many of the AS events are associated
with neurodegenerative brain diseases (NBDs), such as AD and
Parkinson’s disease (PD) (Mills and Janitz, 2012).
In acetyltransferase p300 (which is a new component of cel-
lular aggregates in α-synuclein positive Lewy bodies of patients
affected by PD), a highly disordered regions was found that
displays similarities with prion-like domains, is encoded as an
alternative spliced variant independently of the acetyltransferase
domain, and provides an interaction interface for various mis-
folded proteins, promoting their aggregation (Kirilyuk et al.,
2012). AS of acetylcholinesterase (AChE) produces two neuronal
tissue-specific splice variants, the synaptic or tailed form (AChE-
T) with the C-terminal extension of the common core by a
peptide containing a cysteine, which favors dimerization, and the
read-through form (AChE-R), whose C-terminal extension over
the common core is shorter than that of AChE-T and lacks cys-
teine (Zimmermann, 2013). AChE-T and its C-terminal peptides
T14 and T30 were suggested to play a pivotal, non-hydrolytic
role in neurodegeneration (Greenfield et al., 2008; Halliday and
Greenfield, 2012).
The high degree of AS in the brain is associated with expres-
sion of a larger number of splicing regulators than most other
tissues (de la Grange et al., 2010). Among these brain-specific
splicing regulators are the members of the CUG-BP, Elav-like
www.frontiersin.org July 2014 | Volume 1 | Article 6 | 9
Uversky Pathogenicity of deregulated regulators
family (CELF), also known as Bruno-like (Brunol) proteins. Six
CELF proteins (CELF1-6) and their AS isoforms are responsible
for the regulation of AS of transcripts involved in neuronal func-
tion, and the dysregulation of CELF-mediated AS in the brain
has been implicated in the pathogenesis of some neurological
disorders (Ladd, 2013).
Aberrant alternative splicing in cardiovascular diseases.
Multiple CVDs, such as cardiomyopathies, arrhythmias, and
a number of inherited heart-related conditions are developed
due to the altered AS of sarcomeric genes, ion channels, and
cell signaling proteins (Lara-Pezzi et al., 2013). For example,
clusterin (CLU) or apolipoprotein J is a chaperone for misfolded
proteins that might contribute to survival by reducing oxidative
stress. CLU maintains partially unfolded proteins in a state
appropriate for subsequent refolding by other chaperones, such
as HSPA8/HSC70. Several AS isoforms of CLU are encoded
from a single gene located on chromosome 8 in humans. These
isoforms are ubiquitously expressed in the tissues, and have
been implicated in aging, neurodegenerative disorders, cancer
progression, and metabolic/ CVDs including dyslipidemia,
diabetes, atherosclerosis, and myocardial infarction (MI) (Park
et al., 2014). CLU is predicted to have several long IDPRs
(residues 1–110, 280–350, and 400–449). The highly disor-
dered N-terminal domain is the CLU region most affected by
AS. AS of the IL1RL1 gene encoding interleukin-1 receptor-
like 1 or ST2 protein produces two forms of the protein, a
transmembrane (ST2L) form and a soluble form (sST2), the
levels of which are elevated in serum of CVD patients with
heart failure or MI (Willems et al., 2012). Aberrant AS of
the L-type calcium channel (LTCC, a membrane ion channel
most responsible for calcium entry and excitation-contraction
coupling) is among genetic factors favoring Timothy syndrome,
which is a malady characterized by multiorgan dysfunction
including lethal arrhythmias, webbing of fingers and toes,
congenital heart disease, immune deficiency, intermittent hypo-
glycemia, cognitive abnormalities, and autism (Splawski et al.,
2004).
At the level of individual genes, the AS-produced isoforms
were shown to play diverse roles during heart failure (Lara-
Pezzi et al., 2012). Some of the illustrative examples include:
the AS-driven generation of two non-functional variants of the
sodium channel SCN5A (which, in the norm, controls cardio-
protection by ischemic preconditioning) during heart failure
(Shang et al., 2007); downregulation of the AS variant of the
cell-cycle-regulated kinase (CCRK, which promotes cardiomy-
ocyte growth and survival) in heart failure (Qiu et al., 2008);
production of the AS variants of the troponin I gene that reduce
contraction efficiency (Feng and Jin, 2010); and appearance of
the AS-generated titin isoforms affecting the cardiac stiffness
in individuals with dilated cardiomyopathy (DCM) (Makarenko
et al., 2004); and the improvement of cardiac function after
infarction by the CnAβ1 AS variant of the phosphatase cal-
cineurin (Felkin et al., 2011). Curiously, troponin I (Hoffman
and Sykes, 2008), titin (Ma et al., 2006), and calcineurin (Dunker
et al., 2001) are all known to possess functionally important
IDPRs.
Altered alternative splicing in diabetes. Wolframin is an
890 amino-acid glycoprotein predominantly localized in the
endoplasmic reticulum (ER) encoded by the WFS1 gene. Various
alterations in WFS1 gene including mutations and AS are asso-
ciated with autosomal recessive Wolfram syndrome, autoso-
mal dominant low frequency sensorineural hearing impairment
(LFSNHI) DFNA6/14, some psychiatric diseases, and diabetes
mellitus (Cryns et al., 2003). In type 2 diabetes mellitus, the resis-
tance to insulin is assumed to be caused by changes in the abun-
dance of the AS isoforms of insulin receptor (Sesti et al., 2001).
Normally, the insulin receptor exists in two isoforms, which are
characterized by the absence (Ex11−) or presence (Ex11+) of a 12
amino acid sequence at the C-terminal tail of α-subunit caused by
the AS of exon 11. The Ex11− form binds insulin with two-fold
higher affinity than the Ex11+, a form which is more abundantly
expressed in target tissues from the type 2 diabetic patients. This
alteration in the abundance of two forms might be related to
the insulin resistance and the decreased sensitivity for metabolic
actions of insulin in type 2 diabetes (Imai et al., 1997; Sesti, 2000;
Sesti et al., 2001).
GENETIC FACTORS: ALTERED EXPRESSION OF IDPs AND DISEASE
As it was already pointed out, cells have evolved multiple com-
plex mechanisms during transcription and translation to regulate
the availability of IDPs (Gsponer et al., 2008). Since IDPs are
important players in various signaling and regulatory networks,
their tightly controlled availability represents a very important
factor for the normal functioning of a healthy cell. It was also
proposed that this tight control of the availability of IDPs might
provide fidelity in signaling, regulation, and recognition by min-
imizing the likelihood of unwanted, non-functional interactions,
and inappropriate sequestering of proteins into non-physiological
protein complexes (Gsponer et al., 2008). In agreement with this
hypothesis, a careful analysis of dosage-sensitive genes (i.e., genes
which are harmful when over-expressed) revealed that the pro-
teins encoded by these genes are often intrinsically disordered
and that these genes are tightly regulated at both mRNA and pro-
tein levels, suggesting that this tight control prevents a potentially
deleterious increase in protein concentration under physiological
conditions (Vavouri et al., 2009; Babu et al., 2011).
Aberrant expression of IDPs and cancer
In solid tumors there is a markedly altered pH profile compared
to normal tissues. One of the important players in correspond-
ing pH regulation is the electroneutral Na+, HCO−3 cotrans-
porter (SLC4A7, NBCn1), which is significantly over-expressed
in human mammary carcinomas (Gorbatenko et al., 2014).
Curiously, the N-terminal half of this 1214 residue-long protein is
predicted to be mostly disordered. Altered levels of the collapsin
response mediator proteins (CRMPs, C-terminal tails of which
are predicted to be disordered), were reported for several malig-
nant tumors, such as lung, breast, colorectal, prostate, pancreatic,
and neuroendocrine lung cancer (Tan et al., 2014).
Recently, it was pointed out that several N-glycoproteins are
differentially expressed in some cancerous diseases (Tuccillo et al.,
2014). The illustrative examples of this phenomenon include up-
regulation of alpha-1-antichymotrypsin in HCC (Ishihara et al.,
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2011) and non-small-cell lung carcinoma (NSCLC) (Zeng et al.,
2010); down-regulation of insulin-like growth factor binding pro-
tein 3 in HCC (Chen et al., 2011) and NSCLC (Zeng et al., 2010);
up-regulation of galectin-3-binding protein (Gal3BP or Mac-2
BP) in HCC (Chen et al., 2011) and ovarian cancer (Tian et al.,
2011a); and increased expression of periostin in most ovarian
cancer subtypes (Tian et al., 2011a) and aggressive prostate cancer
(Tian et al., 2011b).
In cancers, high levels of the Sry-containing protein Sox2 are
correlated with poor prognosis and increased proliferation of can-
cer stem cells (Liu et al., 2013). Sox2, a member of the family
of high-mobility group transcription factors, is crucial for early
development and maintenance of undifferentiated ESCs (embry-
onic stem cells). Together with other reprogramming transcrip-
tion factors, Sox2 was predicted to be highly disordered (Xue
et al., 2012c). Recently is has been shown that overexpression and
gene amplification of Sox2 is associated with the development of
squamous cell carcinoma in multiple tissues such as the lung and
esophagus (Liu et al., 2013).
Kruppel-like factor 5 (KLF5) is a basic transcription factor
binding to GC boxes at a number of gene promoters and regu-
lating their transcription. This transcription factor has essential
roles in cell cycle regulation, apoptosis, migration, and differen-
tiation. Expression of KLF5 was found to be abnormal in many
cancer types (Dong and Chen, 2009). As many other transcrip-
tion factors (Liu et al., 2006), KLF5 is predicted to be mostly
disordered.
In uterine leiomyoma, the most common tumors found in
the women of the reproductive age which is characterized by
the excessive extracellular matrix (ECM), levels of integrin-β1
are significantly up-regulated (Chen et al., 2013). Second half
integrin-β1 is predicted to be mostly disordered and this predic-
tion is supported by the structural analysis of this protein, since
structure is known for residues 21–465 (e.g., PDB ID: 3VI3). The
cellular levels of MDMX, which is a heterodimeric partner of
MDM2 and a critical regulator of p53, are noticeably elevated in
tumors with wild-type p53 (Li et al., 2012). Such elevated lev-
els of MDMX contribute to p53 inactivation. Crystal structures
are known for the N-terminal SWIB domain (residues 25–110,
PMID: 2VYR) and the C-terminal region necessary for interac-
tion with UBP2 (residues 429–490, PMID: 2VJE), whereas the
reminder of MDMX is disordered.
Aberrant expression of various members of the S100 pro-
tein family (which is the largest subfamily of calcium binding
proteins of EF-hand type containing at least 25 different mem-
bers) is associated with pathogenesis of various cancers (Chen
et al., 2014). Curiously, since these proteins display a unique
pattern of tissue/cell type specific expression in the norm, dif-
ferent cancer types were shown to be characterized by opposite
alterations in the levels of different members of this interest-
ing family. For example, over-expression of S100A2, S100A3,
S100A6, S100A8/A9, and S100A11 is related to several types of
cancer, whereas other types of cancer are characterized by the
under-expression of these same proteins (Chen et al., 2014). This
remarkable variability in the outputs of the deregulation of levels
of these proteins can be understood by taking into account their
wide functional spectrum, which spreads from to proliferation,
to apoptosis, to metastasis, to tumor microenvironment, and to
cancer stem cells (Chen et al., 2014). Another important factor
defining this variability is intrinsically disordered nature of S100
proteins (Permyakov et al., 2011). In fact, comprehensive bioin-
formatics analysis revealed that these proteins are enriched in
intrinsic disorder, with 62% of them being predicted to be dis-
ordered by at least one of the predictors: 31% are recognized
as “molten globules” and 15% are shown to be in extended
disordered form (Permyakov et al., 2011).
Various cancers are associated with the altered expression of
many subunits of the Mediator complex (Schiano et al., 2014).
Mediator is an evolutionarily conserved large proteinaceous
machine, needed for growth and survival of all cells. A high preva-
lence of IDPRs was reported for various subunits of Mediator
from both Saccharomyces cerevisiae and Homo sapiens, especially
in the Tail and the Middle modules (Toth-Petroczy et al., 2008).
The IDPRs were shown to contribute to function of this impor-
tant complex in at least three different ways, individually serving
as target sites for multiple partners having distinctive structures,
acting as malleable linkers between globular domains, and facil-
itating assembly and disassembly of complexes in response to
regulatory signals (Fuxreiter et al., 2008; Toth-Petroczy et al.,
2008). Over-expression of five out of 13 subunits of an impor-
tant translation-related machinery, human translation initiation
factor eIF3 (which interacts with the 40S ribosomal subunit, and
promotes binding of tRNAMeti and mRNA), is known to cause
malignant transformation (Zhang et al., 2008; Le Quesne et al.,
2010).
Altered expression levels of IDPs in neurodegenerative diseases
An illustrative example of the role of over-expression of a par-
ticular protein in the pathogenesis of a given neurodegenerative
disease is given by the dual-specificity tyrosine phosphorylation-
regulated kinase 1A (DYRK1A) in Down syndrome (Wegiel
et al., 2011). In fact, DYRK1A over-expression deregulate multi-
ple pathways in the developing and aging Down syndrome brain,
affecting hundreds of proteins, including cytosolic, cytoskeletal,
and nuclear proteins, transcription factors (Wegiel et al., 2011).
Over-expressed DYRK1A directly leads to the hyperphosphoryla-
tion of tau and phosphorylation of AS factor controlling balance
between the tau AS isoforms (Wegiel et al., 2011). Although
DYRK1A is an enzyme and therefore is expected to be mostly
ordered, computational analysis revealed that this important
kinase contains two very long disordered tails decorating catalytic
domain (residues 1–150 and 500–763). Alterations in expression
of highly conserved filamentous proteins septins is associated
with variety of neurological conditions, such as Alzheimer’s and
Parkinson’s disease (Peterson and Petty, 2010). Dozens of differ-
ent human septins are encoded by 14 loci (SEPT1-SEPT14), and
all septin proteins contain highly conserved GTPase and poly-
basic domain regions and highly diverged N- and/or C-termini
(Peterson and Petty, 2010), which are predicted to be highly
disordered.
An altered expression of brain-derived neurotrophic factor
(BDNF, N-terminal half of which is predicted to be disor-
dered) was found in postmortem brains and serum from patients
with schizophrenia, Alzheimer’s disease and mood disorders
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(Carlino et al., 2013). Also, in addition to the abnormal hyper-
phosphorylation reported below (see “Aberrant PTMs and neu-
rodegenerative diseases” section below), aberrant expression of
the intrinsically disordered tau protein is known to be associ-
ated with AD and Down syndrome (Cardenas et al., 2012). The
expression levels of glutamate receptor are dramatically altered
in regions of the AD brain possessing the greatest pathological
changes (Proctor et al., 2011). Another illustration of the role of
protein overexpression in neurodegeneration is given by a classi-
cal pathology-related IDP, α-synuclein, where multiplications of
the SNCA gene that encodes this IDP are associated with auto-
somal dominant PD (Eriksen et al., 2005; Elia et al., 2013). One
of the causative agents of SMA, an autosomal recessive neurode-
generative disorder which is a leading genetic cause of infantile
mortality, is deletion of a highly disordered protein, survival
motor neuron-1 (SMN1) (Lorson et al., 2010).
Alterations of IDP expression in cardiovascular diseases
In CVDs, changes in expression levels of connexins (Cxs, which
are intercellular channels forming low-resistance pathways per-
mitting ions and metabolites up to 1 kDa in molecular mass to
flow from cell to cell), such as Cx43, are known to modulate
cell-cell coupling and the path of excitation spreading through-
out the heart (Zhang and Shaw, 2013). C-tail of Cx43 (residues
230–382) is predicted to be highly disordered. Other proteins with
altered expression and activity in major heart diseases, such as
ischemic heart disease, cardiomyopathies, and congestive heart
failure, are sarcoplasmic reticulum Ca2+ ATPases (SERCA) 2a
and 2b, which are crucial for recycling cytosolic Ca2+ into the
lumen of the sarcoplasmic reticulum (SR) (Shareef et al., 2014).
Hart failure, which is the end stage of MI, cardiac hypertrophy,
and hypertension, is characterized by the down-regulation of the
alpha-myosin heavy chain (α-MHC) gene and SERCA genes and
reactivation of specific fetal cardiac genes including atrial natri-
uretic factor and brain natriuretic peptide (Duygu et al., 2013).
In addition to SERCA, altered levels and activities of many other
Ca2+ cycling proteins are related to the heart failure. Among
these Ca2+ cycling proteins responsible for the release and reup-
take of intracellular Ca2+ that drives muscle contraction and
relaxation are the ryanodine receptor 2, cardiac (RyR2), Ca2+
release channel macromolecular complexes, and phospholamban
(Marks, 2013).
Altered expression of the angiotensin-converting enzyme 2
(ACE2) is associated with cardiac and vascular diseases, such as
failing human hearts and atherosclerotic vessels. ACE2 degrades
angiotensin II, which is the main effector of the classic renin-
angiotensin system (RAS) that plays an important role in the
pathophysiology of CVD (Burrell et al., 2013). Elevated levels
of plasma plasminogen activator inhibitor-1 (PAI-1) have been
shown to precede MI in patients (Juhan-Vague et al., 1996;
Ploplis, 2011). In addition for being aberrantly expressed in
various cancers, levels of the Kruppel-like factor 5 (KLF5) are
altered in all vascular smooth muscle cell (VSMC)-related dis-
eases, such as atherosclerosis, restenosis after angioplasty, cardiac
hypertrophy, and hypertension (Dong and Chen, 2009).
Alteration in the composition of ECM proteins, such as
claudin-5, occludin, zona occludens proteins (ZO-1 and ZO-2),
increased levels of some ECM proteins (such as osteopontin,
chondroitin sulfate proteoglycan neurocan, and fibrinogen), and
decreased levels of ECM receptors, such as integrins and dys-
troglycan, are associated with the altered blood-brain barrier
(BBB) found in neurologic diseases, such as stroke (Baeten
and Akassoglou, 2011). Osteopontin is an acidic hydrophilic
glycophosphoprotein that functions as a cell attachment pro-
tein and was predicted to be mostly disordered and shown
to be a typical IDP in solution by multidimensional nuclear
magnetic resonance spectroscopy, synchrotron radiation circu-
lar dichroism spectroscopy, and small-angle X-ray scattering
(Platzer et al., 2011). Many of the listed above proteins are
predicted to possess long IDPRs. Massive parts of neurocan
(residues 350–1050), fibrinogen alpha (residues 100–650), beta
(residues 1–250), and gamma chains (flexible residues with disor-
der scores close to 0.6 are found in regions 65–177 and 318–349),
occludin (residues 300–522), ZO-1 (residues 100–400 and 600–
1600), ZO-2 (residues 100–500 and 900–1190), and dystroglycan
(residues 300–500 and 800–895) are predicted to be highly disor-
dered. In agreement with these predictions, no crystal structure
is available for the monomeric forms of any fibrinogen chain,
whereas crystal structure was solved for a hexameric complex
formed by all three fibrinogen chains (PDB ID: 3GHG, Figure 5).
Importantly, many residues were missing in this crystal struc-
ture (e.g., residues 1–26 and 201–562 in fibrinogen alpha chain,
residues 1–57 and 458–461 in fibrinogen beta chain, and residues
1–13 and 395–411 in fibrinogen gamma chain) indicating that the
corresponding regions remain high flexibility even in their bound
forms.
Altered expression of IDPs in diabetes
Type 2 diabetes, a heterogeneous disorder with hyperglycaemia
caused by impaired insulin secretion and decreased insulin
sensitivity is characterized by aberrant expression of several
important proteins in β-cells and pancreatic islets (Ostenson
and Efendic, 2007). Among the islet proteins, whose lev-
els are altered in type 2 diabetes, are GLUT2, glucokinase,
phosphofructokinase, glucose-6-phosphoisomerase, m-glycero-
phosphate dehydrogenase, pyruvate kinase, KCNJ11/Kir.2, SUR1,
PDX-1, Foxo-1, and IRS-2 (Ostenson and Efendic, 2007).
Markedly decreased expression of a number of SNARE com-
plex proteins [such as syntaxin-1A, SNAP-25, VAMP-2, nSec1
(MUNC18), synaptophysin, and synaptotagmin V] was also
found in pancreatic islets of type 2 diabetic patients (Ostenson
et al., 2006). It has been established that the non-bound SNAP-
25 is mostly disordered in solution (Fasshauer et al., 1997).
In agreement with these data, recent comprehensive bioinfor-
matics analysis revealed that human SNARE proteins possess
FIGURE 5 | Crystal structure of a hexameric complex formed by three
fibrinogen chains, fibrinogen alpha (blue and orange chains), beta (red
and yellow chains), and gamma (gray and tan chains) (PDB ID: 3GHG).
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substantial amount of predicted disorder (Pietrosemoli et al.,
2013).
One of the hallmarks of the type 2 diabetes is diabetic dys-
lipidemia associated with the increased production of very low
density lipoprotein (VLDL) (Verges, 2010). This abnormality
is caused by the aberrant levels of hepatic apolipoprotein B
(ApoB), a protein playing crucial role in the VLDL production
by the liver (Verges, 2010). ApoB is a very large (4536 residues),
mostly ordered protein that is predicted to have several rela-
tively long IDPRs (e.g., residues 299–340 and 506–546). Skeletal
muscle of type 2 diabetic patients shows reduced expression of
mitochondrial proteins peroxisome proliferator-activated recep-
tor gamma coactivator 1-α (PGC-1α), peroxisome proliferator-
activated receptor gamma coactivator 1-β (PGC-1β), and the
mitochondrial fusion protein mitofusin 2 (Mfn2) (Zorzano et al.,
2010). Both PGC-1α and PGC-1β are predicted to be mostly
disordered, and Mfn2 is expected to be mostly ordered, this
protein is predicted to have multiple short IDPRs. Abnormal
expression of insulin-like growth factor (IGF) binding proteins
(IGFBPs) was detected in diabetes and could be used as a sensi-
tive marker of insulin resistance defined as decreased sensitivity
and/or responsiveness to metabolic actions of insulin promoting
glucose disposal (Ruan and Lai, 2010). Several different IGFBPs
are found in the serum, other biological fluids, and tissue extracts.
The members of this superfamily of homologous proteins form
an important link between the insulin and IGF systems (Ruan
and Lai, 2010). Many members of this IGFBP superfamily are
predicted to be either mostly disordered or at least possess long
IDPRs.
One of the serious complications of diabetes is diabetic
nephropathy (Molitch et al., 2003). In fact, 20–30% of patients
with type 1 and or type diabetes mellitus possess nephropathy,
which develops in 40–50% of patients with a 20-year history
of type 1 diabetes mellitus (Thrailkill et al., 2009). One of the
hallmarks of diabetic nephropathy is altered expression or acti-
vation of matrix metalloproteinases (MMPs), such as collage-
nases, gelatinases, stromelysins, matrilysins, and membrane-type
MMPs, which have the capacity to breakdown all components
of the ECM (Thrailkill et al., 2009). Another protein associated
with diabetic nephropathy is angiotensin I-converting enzyme
(ACE), elevated levels of which are found in this pathology (Lely
et al., 2007). Although all MMPs and ACE are enzymes and
are expected to be mostly ordered, they do possess regions of
predicted disorder.
NON-GENETIC FACTORS PROMOTING PATHOGENICITY OF IDPs
Abnormal posttranslational modifications
Abnormal PTMs and cancer. Functions of many IDPs and
IDPRs are controlled, modulated, and regulated by various PTMs.
Therefore, aberrant PTMs are commonly associated with several
human diseases. In fact, all major PTMs, such as glycosyla-
tion, phosphorylation, acetylation, ubiquitination, methylation,
and palmitylation, have been observed to be altered in cancer,
affecting key cellular pathways including signal transduction, cell
membrane receptor function, and protein-protein interactions
(Markiv et al., 2012). For example, abnormal glycosylation of
some glycoproteins due to deregulated glycosyltransferases and
glycosidases is known to be a common phenomenon of many
malignancies, including CRC, where elevated levels of the cell-
surface α2,6-linked sialic acids have been linked to metastatic
spread and therapeutic resistance of this cancer (Park and Lee,
2013). The widespread and diverse PTMs of histones, important
nuclear IDPs (Peng et al., 2012) that are crucial for regulated gene
expression and for a variety of epigenetic mechanisms, are under
very tight and complex spatial and temporal control (Campbell
and Turner, 2013). This spatial and temporal regulation of histone
modifications is distorted in malignancies on both a genome-
wide and discrete gene loci levels (Campbell and Turner, 2013).
For example, excessive aberrant acetylation and methylation of
specific histone residues have been found in CRC (Gargalionis
et al., 2012). Also, alterations of different PTMs at lysine residues
(such as acetylation, methylation, ubiquitination, and sumoyla-
tion) of proteins involved in DNA repair is often associated with
genomic instability, which is the major cause of different dis-
eases, especially cancer (Chatterjee et al., 2012). It has been even
proposed that the analysis of histone modifications in circulat-
ing nucleosomes can be used for the diagnosis and estimation of
prognosis in the CRC patients (Gezer and Holdenrieder, 2014).
Aberrant glycosylation is a well-established event in oncoge-
nesis and cancer progression (Tuccillo et al., 2014), and many
biomarkers used for diagnosis, prognosis, and prediction of many
cancers are N-linked glycosylated proteins (Drake et al., 2006;
Tian and Zhang, 2013). For example, malignant transformation
of cells is associated with aberrant glycosylation of mucins, abnor-
mal branching of N-glycans, and increased presence of sialic acid
on proteins and glycolipids (Hauselmann and Borsig, 2014).
In addition to translational regulation discussed above, cancer-
related activities of Sox2 protein are controlled by various PTMs
(Liu et al., 2013). In fact, many sites of Sox2 can be modified
through phosphorylation, acetylation, ubiquitination, methyla-
tion, and SUMOylation, and based on which sites are modified,
Sox2 displays different normal and pathological activities (Liu
et al., 2013). Ubiquitination-deubiquitination of a master tran-
scriptional repressor that acts as a tumor suppressor or oncogene
in diverse types of cancers, the RE-1 silencing transcription fac-
tor (REST) or neuron-restrictive silencer factor (NRSF), controls
levels of this protein in cancer, and abnormal upregulation of
REST has been found in medulloblastoma, neuroblastoma, and
glioblastoma (Huang and Bao, 2012). As many other transcrip-
tion factors (Liu et al., 2006; Guo et al., 2012), REST/NRSF is
predicted to be highly disordered.
It is important to remember that alterations in PTMs of
many disease-related proteins are typically produced by alter-
ations of modifying enzymes. For example, aberrant phosphory-
lation, acetylation, methylation, sumoylation, and ubiquitination
of the AR found in prostate cancer is caused by alterations of
enzymes that modify the AR (Gioeli and Paschal, 2012). Also, his-
tone acetyltransferases (HATs) and histone deacetylases (HDACs)
are two classes of enzymes regulating histone acetylation whose
altered activity has been identified in several cancers (Di Gennaro
et al., 2004).
Aberrant PTMs and neurodegenerative diseases. InHuntington’s
disease (HD), a genetic neurodegenerative disorder caused by
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CAG expansions in the gene encoding Huntingtin protein
(Htt), alterations of several histone PTMs are found, including
phosphorylation, acetylation, methylation, ubiquitination, and
polyamination (Moumne et al., 2013). Various PTMs of Htt itself,
such as phosphorylation, sumoylation, ubiquitination, acetyla-
tion, proteolytic cleavage, and palmitylation, are also signifi-
cantly altered in HD, resulting in changes in clinical phenotypes
(Ehrnhoefer et al., 2011). In AD, which is a neurodegenerative
disorder characterized by the progressive cognitive decline and by
accumulation of insoluble aggregates of two proteins in the brain,
amyloid-β (Aβ) and the microtubule-associated protein tau, Aβ
levels and tau aggregation are impacted by altered sumoylation
(Lee et al., 2013). Aberrant phosphorylation of the microtubule-
associated protein tau is known to be associated with AD pathol-
ogy and pathogenesis of other tauopathies (Hernandez and Avila,
2007). In fact, in AD, tau is abnormally hyperphosphorylated to
a stoichiometry of at least three-fold greater than normal tau.
This hyperphosphorylation is believed to be a major driving force
for pathological tau aggregation, leading to the formation of a
histopathological hallmark of the disease, paired helical filaments
assembled from neurofibrillary tangles. Abnormal hyperphos-
phorylation and concomitant aggregation of tau is also a char-
acteristic feature of several other tauopathies (Wang et al., 2013).
Abnormal hyperphosphorylation of a RNA/DNA binding protein
TDP-43 (TAR DNA binding protein 43) was shown to accumu-
late in the cytoplasm of neuronal cells of patients affected by
fronto temporal lobar degenerations (Buratti and Baralle, 2008).
TDP-43, which is known to control both normal and patholog-
ical RNA splicing events, is predicted to have a long disordered
C-tail (residues 250–414). In Huntington disease, mutations in
huntingtin (which normally undergoes different PTMs, such as
phosphorylation, SUMOylation, ubiquitination, acetylation, pro-
teolytic cleavage, and palmitoylation) significantly alters PTMs
leading to changes in the clinical phenotype (Ehrnhoefer et al.,
2011).
Prion diseases are characterized by the conversion of a soluble
form of the glycoprotein prion protein (PrPC) to the abnor-
mal (infectious) scrapie form (PrPSc) (Gains and LeBlanc, 2007).
NMR analysis revealed that human PrPC is a hybrid protein
that contains a C-terminal globular domain extending from
residues 125–228, and an N-terminal disordered tail (Zahn et al.,
2000). Recent study revealed that the transmissible spongiform
encephalopathy (TSE) strain characteristics are affected by the
glycosylation status of PrP (Cancellotti et al., 2013). This conclu-
sion is based on the comparative study of the infectious properties
of the isolates of three TSE strains passaged through transgenic
mice with PrP devoid of glycans at the first, second or both N-
glycosylation sites. This analysis revealed that the strain-specific
characteristics of the TSE strain changed when PrPSc was devoid
of one or both glycans suggesting that the PTMs of PrP may
play a role in altering the infectious properties of a TSE strain
(Cancellotti et al., 2013).
Altered PTMs in cardiovascular diseases. Altered PTMs of the
voltage-gated Na channel isoform 1.5 (NaV1.5) contribute to
the aberrant functions of this important protein associated with
acquired cardiac disorders, including arrhythmias and heart
failure (Herren et al., 2013). NaV1.5 is the pore forming α-subunit
of the voltage-gated cardiac Na channel, which is responsible
for the initiation and propagation of cardiac action potentials.
Abnormal PTMs affect localization and gating potential of this
protein (Herren et al., 2013). Abnormal phosphorylation of
myosin light chain and troponins I and T, and, potentially, altered
oxidation and glycation of sarcomeric proteins represent very
important mechanisms underlying the myofilament dysfunction
in DCM (LeWinter, 2005). Earlier, troponin I was shown to pos-
sess functionally important disordered regions (Hoffman et al.,
2006). Furthermore, subsequent comprehensive bioinformatics
analysis revealed that different troponin I isoforms are character-
ized by different abundance and distribution of intrinsic disorder
(Hoffman and Sykes, 2008). This isoform-specific disorder vari-
ability was suggested to have potential mechanistic significance
being responsible for modulation of the extent to which con-
formational fluctuations in tropomyosin are communicated to
the troponin complex (Hoffman and Sykes, 2008). Troponin T
is predicted to be mostly disordered.
Since constitutive nitric oxide (NO) synthases (NOS) are
among the crucial factors responsible for the maintenance of
myocardial Ca2+ homeostasis, myocardial relaxation and dis-
tensibility, and protection from arrhythmia and abnormal stress
stimuli, the aberrant regulation and dysfunction of these impor-
tant proteins in hypertension, hemodynamic overload, and atrial
fibrillation are known to lead to the production of super-
oxide instead of NO (Carnicer et al., 2013; Shibata et al.,
2013). Deregulation of NOS1 and NOS3 phosphorylation and
glutathionylation are potent contributors to vascular disease,
myocardial ischemia, reperfusion injury,MI, cardiac hypertrophy,
and failure (Carnicer et al., 2013). NOS1 and NOS3 are predicted
to have long IDPRs.
Abnormal PTMs in diabetes. Maintenance of metabolic home-
ostasis is controlled by some nuclear receptors, e.g., by the sub-
family of the peroxisome proliferator-activated receptor (PPARs),
which consists of three members (PPAR-α, PPAR-γ, and PPAR-δ)
encoded by different genes and is involved in a wide range of
physiological processes affecting lipid homeostasis, inflammatory
responses, adipogenesis, insulin sensitivity, reproduction, wound
healing, and carcinogenesis (Escher and Wahli, 2000; Lazennec
et al., 2000; Mandard et al., 2004) PPARs has similar structural
topology, possessing an N-terminal ligand-independent transac-
tivation domain (AF-1), a two zinc-finger DNA-binding domain,
a hinge domain, and a C-terminal ligand-binding domain con-
taining a ligand responsive activation domain (AF-2). Structural
analysis of PPAR-γ revealed that this protein has several long
regions of missing electron density (PDB ID: 3DZY), such as
residues 1–211, 238–298, and 443–477 (Chandra et al., 2008;
Fuxreiter et al., 2011). The N-tails of PPAR-α (residues 1–96) and
PPAR-δ (residues 1–70) are predicted to be disordered. Curiously,
obesity (which one of themajor underlying cause of themetabolic
syndrome) was shown to promote phosphorylation of PPAR-
γ at Ser273 (pSer273), and this PTM is correlated with the
dysregulation of a subset of PPAR-γ target genes (such as the
insulin-sensitizing adipokines such as adiponectin and adipsin),
many of which are dysregulated in obesity (Choi et al., 2010).
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Glycation of fibrinogen is a very common PTM detected in
diabetes (Hammer et al., 1989; Henschen-Edman, 2001). This is
an important finding since even modest degrees of fibrinogen
modification can alter the rate of assembly of fibrin monomers
into a fibrin clot and the fiber structure and packing, thereby con-
tributing to the increased atherothrombotic risk associated with
hyperhomocysteinemia and diabetes (Hoffman, 2008). The pecu-
liarities of disorder distribution in various chains of fibrinogen
were already discussed (see section “Alterations of IDP expression
in cardiovascular diseases”).
Although the modification of nuclear and cytoplasmic
proteins at their serine and threonine residues by the post-
translational attachment of O-linked N-acetylglucosamine
(O-GlcNAc) is crucial for the regulation of various cellular
processes, prolonged increases inO-GlcNAcylation and sustained
increases in O-GlcNAc levels have been implicated in glucose
toxicity and insulin resistance (McLarty et al., 2013). It has
been also emphasized that there is a complex interplay between
phosphorylation and O-GlcNAcylation, as a result of which
proteins can be both O-GlcNAcylated and phosphorylated,
since O-GlcNAc and phosphate moieties compete for the same
protein residues, serine, and threonine (McLarty et al., 2013).
Obviously, this contributes a new level of complexity for protein
regulation by PTMs under conditions of globally elevated
GlcNAcylation, since increased GlcNAcylation was shown to
affect phosphate stoichiometry at most of the sites involved in
active phosphorylation-dephosphorylation cycling (Wang et al.,
2008). Among 711 phosphopeptides for which phosphorylation
dynamics was analyzed, GlcNAcylation resulted in lower phos-
phorylation at 280 sites and caused increased phosphorylation
at 148 sites (Wang et al., 2008). Three hundred and eighty one
proteins affected by such dual PTMization possessed a wide spec-
trum of biological functions, such as chaperones, cytoskeleton
regulatory proteins, metabolic enzymes, kinases, transcription
factors, and RNA processing proteins (Wang et al., 2008). From
the list of functions it is clear that many of these proteins are
either IDPs or hybrid proteins possessing long functional IDPRs.
In fact, protein involved in chaperon functions, RNA binding
and processing, and regulation of cytoskeleton and transcription
are all expected to be disordered based on the associative study
correlating Swiss-Prot functional keywords and protein intrinsic
disorder (Vucetic et al., 2007; Xie et al., 2007a,b), and on existing
experimental data for some members of these functional classes.
Abnormal proteolytic degradation
It is known that proteolytic digestion is orders of magnitude
faster in unstructured as compared to structured protein regions
(Polverino de Laureto et al., 1995; Fontana et al., 1997, 1986,
2004; Iakoucheva et al., 2001; de Laureto et al., 2006). Therefore,
it is extremely important for the protein cleavage process that the
sites of cleavage would be located in regions that lack structure or
possess high structural flexibility.
Among the multiple modifications affecting aggregation
propensity of the intrinsically disordered soluble protein tau and
thereby contributing to the neurofibrillary pathology in AD and
other tauopathies is abnormal truncation (Kovacech and Novak,
2010). In fact, the progression of AD is at least partially linked
to the existence of several site-specific tau cleavages generating
a multitude of various truncated forms. It has been shown that
tau truncation alone is sufficient to induce the complete cascade
of neurofibrillary pathology suggesting that proteolytical abnor-
malities in the stressed neurons and production of aberrant tau
cleavage products are important events in the AD pathogenesis
(Kovacech and Novak, 2010).
High levels of the truncated form Gli3R of a glioma-associated
oncogene 3 (Gli3) are related to various human limb malfor-
mations (Ruiz i Altaba, 1999; Hui and Angers, 2011). Glioma-
associated oncogene family members 1, 2, and 3 (Gli1, Gli2, and
Gli3) are specific transcription factors for controlling the signal
transduction of the Hedgehog (Hh) pathway, one of the key regu-
latory networks involved in animal development (Jiang and Hui,
2008). A peculiar feature of the Gli family members is that the
regulated proteolytic processing can convert some Gli proteins
from a full-length transcriptional activator form into a truncated
repressor form (Hui and Angers, 2011). The appearance of the
Gl3R form represents a result of limited proteolysis of Gli3 by the
proteasome (Hui and Angers, 2011). Being transcriptional activa-
tors possessing multiple zinc finger motifs, all three members of
the Gli family are predicted to be extensively disordered.
Proteolytic processing of cell-surface proteoglycans (PGs)
known as ectodomain shedding of syndecans is related to the
facilitation of cancer and promotion of the cancer cell motility
and invasion thereby increasing aggressiveness of various tumors
(Theocharis et al., 2010). Among the PGs with aberrant prote-
olytic degradation patterns in cancers are versican, aggrecan, bre-
vican, decorin, perlecan, glypicans, and syndecans (Theocharis
et al., 2010). The majority of these proteins are characterized
by moderate to high levels of predicted disorder. In the crys-
tal structure of human glypican-1 (PDB ID: 4AD7), residues
24–28, 350–361, 406–412, and 476–529 are located within the
regions with missing electron density. Similarly, abnormal prote-
olytic degradation of collagens [which are known to be enriched
in intrinsic disorder (Peysselon et al., 2011)] contributes to the
cancer pathogenesis via multiple routs via affecting the effi-
ciency of cancer cell invasion, activation of integrins, cancer cell
proliferation, angiogenesis (Egeblad et al., 2010).
Defective trafficking of IDPs and hybrid proteins
It has been pointed out that defects in trafficking of some pro-
teins might represent an important mechanism in many diseases
(Delisle et al., 2004). Many of these pathogenic proteins with
defective trafficking are IDPs or hybrid proteins with long IDPRs.
An illustrative example is given by the low-density lipoprotein
receptor (LDLR), mutations in which are associated with famil-
ial hypercholesterolemia (Delisle et al., 2004). It was pointed
out that ≈50% of LDLR mutations act to disrupt receptor pro-
tein trafficking from the ER to the Golgi complex (Hobbs et al.,
1990; Goldstein and Brown, 2001). Structural and bioinformatics
analysis revealed that LDLR possesses long IDPRs. For example,
residues 4–275, 457–464, and 714–788 (PDB ID: 3M0C) comprise
regions with missing electron density, which typically correspond
to IDPRs (Le Gall et al., 2007).
In cystis fibrosis, multiple mutations in cystic fibrosis trans-
membrane conductance regulator (CFTR) cause defective protein
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trafficking, where the mutated CFTR is retained in the ER (Cheng
et al., 1990). The most well-studied mutation affecting normal
trafficking of CFTR is the deletion of the codon for a phenylala-
nine at position 508 (F508) of CFTR protein and is found in
70% of affected patients (Cheng et al., 1990; Delisle et al., 2004).
Region 708–831 of CFTR, which is the functional regulatory (R)
domain phosphorylation of which domain initiates Cl− channel
activity of CFTR, was shown to be predominantly disordered in
solution (Ostedgaard et al., 2000).
Mutations in connexin 32 (Cx32), which is an integral gap
junction membrane protein forming channels for the transmis-
sion of electrical signals and diffusion of small ions andmolecules
between coupled cells, are known to be associated with the
Charcot-Marie-Tooth disease (CMTX) (Bergoffen et al., 1993;
Delisle et al., 2004). Some CMTX mutations found in this com-
plex polygenic neuropathic disorder, that constitutes the most
common form of inheritable disease in the peripheral nervous
system, result in the Cx32 protein that is synthesized but not
properly transported to the plasma membrane (Delisle et al.,
2004). C-terminal tail of Cx32 protein (residues 221–283) is
predicted to be extensively disordered.
In the norm, the vasopressin-regulated aquaporin-2 channel
(AQP2) is found in the kidney at distinct sites along nephrons
and collecting ducts (Nielsen et al., 2002). Several mutations in
AQP2 are associated with impaired transport from the ER and
development of the non-X-linked nephrogenic diabetes insipidus
(NDI), a hereditary malady characterized by the inability to con-
centrate the urine resulting in excessive urine production and
thirst (Tamarappoo and Verkman, 1998) Being a transmembrane
protein, AQP2 is expected to be mostly structured. However,
computational analysis revealed that it has two long predicted
IDPRs, residues 147–164 and 238–271.
CONCLUDING REMARKS
Intrinsic disorder is very common in proteins, plays various roles
in numerous protein functions and is tightly controlled in the
healthy cells. Among the major functions of IDPs are recogni-
tion as well as regulation and control of various signaling events.
Normally, function and abundance of IDPs are tightly controlled.
The breaking these proteins out of control brings havoc and ini-
tate various pathological events. In fact, IDPs and hybrid proteins
containing ordered domains and functional IDPRs are commonly
involved in the pathogenesis of human diseases. The crucial roles
of IDPs and hybrid proteins in promoting and supporting the
disease states are obvious from several illustrative examples of
well-characterized disease-related IDPs, such as p53, α-synuclein,
PTEN, tau protein, prion protein, etc., as well as from the results
of comprehensive bioinformatics studies. The high degree of
involvement of IDPs in the pathogenesis of various diseases is
determined by the unique structural and functional properties of
these proteins. IDPs and IDPRs frequently serve as major cellu-
lar regulators, recognizers and signal transducers. Their normal
functionality is tightly controlled and modulated via a wide spec-
trum of PTMs and AS. Many IDPs/IDPRs can fold (completely
or partially) upon interaction with corresponding binding part-
ners and possess multiple binding specificities, enabling them to
participate in one-to-many and many-to-one interactions.
Distortion of any of the mechanisms controlling IDP/IDPR
functionality can be detrimental. Some disease-related proteins
have an intrinsic propensity to form pathologic conformations,
whereas other proteins require some external factors, such as
impaired interactions with chaperones, intracellular or extra-
cellular matrices, other proteins, small molecules, and addi-
tional endogenous factors, to gain conformational alterations
leading to increased propensities for misfolding and dysfunc-
tion. Often, protein pathogenicity originates from altered splic-
ing, chromosomal translocations, abnormal expression levels,
or impaired trafficking. Formation of pathologic conformations
can also be triggered by aberrant PTMs and increased degra-
dation propensities. In other words, any cellular event that
affects the functionality, foldability, abundance, or cellular dis-
tribution of these important players may cause pathological
transformations.
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